Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: LUC7L

Gene summary for LUC7L

Gene summary.

Gene information	Species	Human
	Gene symbol	LUC7L
	Gene ID	55692
	Gene name	LUC7 like
	Gene Alias	LUC7B1
	Cytomap	16p13.3
	Gene Type	protein-coding
	GO ID	GO:0000245
	UniProtAcc	Q1W6G4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
55692	LUC7L	HTA11_3410_2000001011	Human	Colorectum	AD	1.00e-02	-3.25e-01	0.0155
55692	LUC7L	A015-C-203	Human	Colorectum	FAP	1.87e-22	1.94e-01	-0.1294
55692	LUC7L	A015-C-204	Human	Colorectum	FAP	3.02e-02	2.22e-01	-0.0228
55692	LUC7L	A002-C-201	Human	Colorectum	FAP	1.85e-07	1.51e-01	0.0324
55692	LUC7L	A001-C-119	Human	Colorectum	FAP	1.20e-16	6.63e-01	-0.1557
55692	LUC7L	A001-C-108	Human	Colorectum	FAP	5.02e-15	2.76e-01	-0.0272
55692	LUC7L	A002-C-205	Human	Colorectum	FAP	2.14e-19	3.08e-01	-0.1236
55692	LUC7L	A001-C-104	Human	Colorectum	FAP	2.57e-07	3.21e-01	0.0184
55692	LUC7L	A015-C-006	Human	Colorectum	FAP	2.78e-12	2.99e-01	-0.0994
55692	LUC7L	A015-C-106	Human	Colorectum	FAP	1.03e-08	1.06e-01	-0.0511
55692	LUC7L	A002-C-114	Human	Colorectum	FAP	1.64e-11	1.77e-01	-0.1561
55692	LUC7L	A015-C-104	Human	Colorectum	FAP	3.89e-26	2.74e-01	-0.1899
55692	LUC7L	A001-C-014	Human	Colorectum	FAP	3.66e-09	1.59e-01	0.0135
55692	LUC7L	A002-C-016	Human	Colorectum	FAP	1.70e-13	8.73e-02	0.0521
55692	LUC7L	A015-C-002	Human	Colorectum	FAP	2.37e-05	5.51e-02	-0.0763
55692	LUC7L	A001-C-203	Human	Colorectum	FAP	2.75e-07	1.50e-01	-0.0481
55692	LUC7L	A002-C-116	Human	Colorectum	FAP	9.86e-24	8.67e-02	-0.0452
55692	LUC7L	A014-C-008	Human	Colorectum	FAP	5.08e-09	1.46e-01	-0.191
55692	LUC7L	A018-E-020	Human	Colorectum	FAP	7.04e-14	2.26e-01	-0.2034
55692	LUC7L	F034	Human	Colorectum	FAP	1.36e-17	2.54e-01	-0.0665

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:002261323	Lung	MIAC	ribonucleoprotein complex biogenesis	44/967	463/18723	7.38e-05	3.47e-03	44
GO:000037723	Lung	MIAC	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	33/967	320/18723	1.27e-04	5.13e-03	33
GO:000039823	Lung	MIAC	mRNA splicing, via spliceosome	33/967	320/18723	1.27e-04	5.13e-03	33
GO:000037523	Lung	MIAC	RNA splicing, via transesterification reactions	33/967	324/18723	1.61e-04	6.19e-03	33
GO:002261320	Oral cavity	OSCC	ribonucleoprotein complex biogenesis	333/7305	463/18723	8.28e-48	5.24e-44	333
GO:000838020	Oral cavity	OSCC	RNA splicing	308/7305	434/18723	2.43e-42	7.70e-39	308
GO:000037519	Oral cavity	OSCC	RNA splicing, via transesterification reactions	225/7305	324/18723	5.20e-29	2.99e-26	225
GO:000037719	Oral cavity	OSCC	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	221/7305	320/18723	5.50e-28	2.18e-25	221
GO:000039819	Oral cavity	OSCC	mRNA splicing, via spliceosome	221/7305	320/18723	5.50e-28	2.18e-25	221
GO:007182620	Oral cavity	OSCC	ribonucleoprotein complex subunit organization	152/7305	227/18723	1.05e-17	1.01e-15	152
GO:002261820	Oral cavity	OSCC	ribonucleoprotein complex assembly	146/7305	220/18723	1.53e-16	1.23e-14	146
GO:00002456	Oral cavity	OSCC	spliceosomal complex assembly	45/7305	79/18723	9.13e-04	4.81e-03	45
GO:0022613110	Oral cavity	LP	ribonucleoprotein complex biogenesis	259/4623	463/18723	7.20e-48	2.25e-44	259
GO:0008380110	Oral cavity	LP	RNA splicing	237/4623	434/18723	1.82e-41	3.79e-38	237
GO:0000375110	Oral cavity	LP	RNA splicing, via transesterification reactions	181/4623	324/18723	1.36e-33	1.70e-30	181
GO:0000377110	Oral cavity	LP	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	179/4623	320/18723	2.48e-33	2.22e-30	179
GO:0000398110	Oral cavity	LP	mRNA splicing, via spliceosome	179/4623	320/18723	2.48e-33	2.22e-30	179
GO:0071826110	Oral cavity	LP	ribonucleoprotein complex subunit organization	130/4623	227/18723	7.54e-26	3.63e-23	130
GO:0022618110	Oral cavity	LP	ribonucleoprotein complex assembly	125/4623	220/18723	1.76e-24	6.91e-22	125
GO:000024513	Oral cavity	LP	spliceosomal complex assembly	34/4623	79/18723	2.65e-04	2.75e-03	34

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

LUC7L

insertion

In_Frame_Ins

novel

c.414_415insGGCCAGCTATGGTGGCTCTTGGCTTTAGTCTCAGCTGTTCGGGAG

p.Ala138_Lys139insGlyGlnLeuTrpTrpLeuLeuAlaLeuValSerAlaValArgGlu

p.A138_K139insGQLWWLLALVSAVRE

Q9NQ29

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

LUC7L

SNV

Missense_Mutation

rs770266344

c.965C>T

p.Ala322Val

p.A322V

Q9NQ29

protein_coding

deleterious_low_confidence(0.01)

benign(0.022)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

LUC7L

SNV

Missense_Mutation

novel

c.454T>C

p.Ser152Pro

p.S152P

Q9NQ29

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

LUC7L

SNV

Missense_Mutation

c.740N>C

p.Arg247Thr

p.R247T

Q9NQ29

protein_coding

deleterious(0.03)

benign(0.432)

TCGA-JX-A3Q0-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

LUC7L

SNV

Missense_Mutation

c.740N>C

p.Arg247Thr

p.R247T

Q9NQ29

protein_coding

deleterious(0.03)

benign(0.432)

TCGA-UC-A7PG-06

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

LUC7L

SNV

Missense_Mutation

c.71N>A

p.Thr24Asn

p.T24N

Q9NQ29

protein_coding

tolerated(0.31)

benign(0.03)

TCGA-AA-3815-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

LUC7L

SNV

Missense_Mutation

rs764753668

c.1021N>T

p.Arg341Trp

p.R341W

Q9NQ29

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.451)

TCGA-CK-5913-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

LUC7L

SNV

Missense_Mutation

novel

c.260N>A

p.Met87Lys

p.M87K

Q9NQ29

protein_coding

deleterious(0)

possibly_damaging(0.484)

TCGA-AG-A01N-01

Colorectum

rectum adenocarcinoma

Female

>=65

III/IV

Chemotherapy

capecitabine

LUC7L

SNV

Missense_Mutation

rs772200033

c.811N>T

p.Arg271Cys

p.R271C

Q9NQ29

protein_coding

deleterious(0.03)

probably_damaging(0.982)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

LUC7L

SNV

Missense_Mutation

novel

c.611N>A

p.Arg204His

p.R204H

Q9NQ29

protein_coding

deleterious(0)

possibly_damaging(0.581)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1